Evidence map›Paper›PMID 17695247›Full record

ReviewImmunologic research2007

Initiation of primary anti-vaccinia virus immunity in vivo.

Matthew A Fischer, Christopher C Norbury

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew A FischerDepartment of Microbiology and Immunology, Pennsylvania State University, Milton S. Hershey College of Medicine, Hershey, PA 17033, USA.
Christopher C Norbury

Funding

Pathways of Antigen Presentation to CD8 T Cells In VivoR01AI056094 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI NORBURY, CHRISTOPHER C · 2003 to 2013
$3.1M
Leukotrienes in Innate and Adaptive Antiviral ImmunityR01AI070537 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI NORBURY, CHRISTOPHER C · 2006 to 2009
$1.4M
Pathways of Antigen Presentation to CD8 T Cells In VivoR56AI056094 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI NORBURY, CHRISTOPHER C · 2008 to 2008
$384k
NIAID NIH HHS AI056094NIAID NIH HHS AI070537
6 · The paper itself

Abstract

The primary focus of our work is the initiation of an antiviral immune response. While we employ many experimental systems to address this fundamental issue, much of our work revolves around the use of vaccinia virus. Concerns over the negative effects of vaccination have prevented the return of the smallpox immunization program to the general population and underscored the importance of understanding the primary immune response to vaccinia virus. This response is comprised of a complex symphony of immune system components employing a variety of different mechanisms. In this review, we will both highlight the roles of many of these components and touch on the applications of vaccinia virus in the laboratory and the clinic.

Indexed as

AnimalsHumansPrimatesSmallpox VaccineVacciniaVaccinia virusSmallpox Vaccine

Identifiers

PMID17695247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.